Imara announced that the FDA has granted fast-track status to its experimental drug IMR-687, being developed to diminish sickling of red blood cells in patients with sickle cell disease. The investigational treatment is being evaluated in a Phase IIa trial with 54 patients who have sickle cell anemia.
Fast-track status granted to Imara's sickle cell disease drug
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.